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CDK1-PDK1-PI3K/Akt signaling pathway regulates
embryonic and induced pluripotency
Xiao Qi Wang*,1,2, Chung Mau Lo1, Lin Chen1, Elly S-W Ngan1, Aimin Xu3 and Randy YC Poon4
The mechanisms of how signaling pathways are coordinated and integrated for the maintenance of the self-renewal of human
embryonic stem cells (hESCs) and the acquisition of pluripotency in reprogramming are still only partly understood. CDK1 is a key
regulator of mitosis. Recently, CDK1 has been shown to be involved in regulating self-renewal of stem cells, even though the
mechanistic role of how CDK1 regulates pluripotency is unknown. In this report, we aim to understand how CDK1 can control
pluripotency by reducing CDK1 activity to a level that has no effect on cell cycle progression. We demonstrated that high levels of
CDK1 is associated with the pluripotency stage of hESCs; and decreased CDK1 activity to a level without perturbing the cell cycle
is sufficient to induce differentiation. CDK1 specifically targets the phosphorylation of PDK1 and consequently the activity of PI3K/
Akt and its effectors ERK and GSK3β. Evidence of the reversion of inactive CDK1-mediated differentiation by the inhibition of Akt
signaling effectors suggests that the CDK1-PDK1-PI3K/Akt kinase cascade is a functional signaling pathway for the pluripotency
of hESCs. Moreover, cyclin B1-CDK1 complexes promote somatic reprogramming efficiency, probably by regulating the maturation
of induced pluripotent stem cells (iPSCs), as cyclin B1 stimulates a higher cellular level of LIN28A, suggesting that monitoring iPSC
factors could be a new path for the enhancement of reprogramming efficiency. Together, we demonstrate an essential role for the
CDK1-PDK1-PI3K/Akt kinase signaling pathway in the regulation of self-renewal, differentiation, and somatic reprogramming,
which provides a novel kinase cascade mechanism for pluripotency control and acquisition.
Cell Death and Differentiation (2017) 24, 38–48; doi:10.1038/cdd.2016.84; published online 16 September 2016
CDK1 is one of the most pleiotropic cell cycle regulators;
it not only primarily interacts with cyclin B to drive the G2-M
transition but also binds to other interphase cyclins (cyclin D1,
E, and A) to regulate G1 progression and G1-S transition.
1
Cdk1 alone is sufficient to drive mammalian cell cycle
progression in knockout mice lacking other Cdks, indicating
that Cdk1 can compensate for other interphase Cdks during
embryonic development.2 However, liver-specific deletion of
Cdk1 is well tolerated and does not impair liver regeneration.3
Cdk1 is also essential for meiosis in mouse oocytes,4 and the
suppression of Cdk1 leads to the differentiation of mouse
trophoblast stem cells into giant cells.5 Recently, it has been
demonstrated that Cdk1/CDK1 is required for self-renewal in
both mESCs and human embryonic stem cells (hESCs),6,7
which might be related to its interaction with Oct4.8,9
CDK1/CDK2 potentially regulates a large number of
substrates (at least 1220) during hESC differentiation.10
All of these studies point to the association of CDK1 with
pluripotency, although there has been no study demo-
nstrating the mechanistic role of how CDK1 regulates
pluripotency.
Self-renewal and pluripotency of ESCs are maintained by
auto-regulatory networks involving the core transcriptional
factors NANOG, OCT4, and SOX2, as well as chromatin
remodeling complexes and epigenetic modifiers.11 Moreover,
the activation of pluripotency genes and the suppression of
lineage-determined genes require the integration of multiple
internal and external signaling pathways of which the
developmental differences betweenmESCs and hESCs could
affect their differential responses to signaling regulation.12
In hESCs, NODAL/ACTIVIN induces SMAD2/3 signaling and
the key target gene NANOG for self-renewal. NODAL/
ACTIVIN together with hyperactive PI3K/Akt signaling, which
is stimulated by the growth factors bFGF and IGFs,
suppresses ERK activity and dephosphorylation of GSK3β,
these pathways contribute to the maintenance of
pluripotency.13–16 In contrast to hESCs, the primary function
of PI3K/Akt in naive mESCs is to suppress Gsk3β activity
through Gsk3β hyperphosphorylation, which allows Nanog
and c-Myc to maintain pluripotency.17 So far, only a few cell
signaling pathways have been shown to be important for
hESC pluripotency, and a possible link between the cell
signaling pathways and basic cellular properties, such as cell
cycle and cell cycle regulators, has not been well addressed.
Here, we investigate the role of CDK1 in the biology of hESCs.
In addition to being a critical cell cycle regulator, our results
identify the novel CDK1-PDK1-PI3K/Akt kinase cascade as an
important signaling pathway for the control and acquisition of
pluripotency.
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Results
High levels of CDK1 is associated with the pluripotency
stage of hESCs. Cdk1 is indispensable and cannot be
compensated by interphase Cdks during early embryonic
development,2,3 indicating a potential in controlling pluripo-
tency in addition to its function as a cell cycle regulator.
However, the existence of a direct association between CDK1
and pluripotency state has not been addressed. To under-
stand this association, we found that hESCs contained a high
level of CDK1. Upon embryoid body (EB)- and retinoic acid-
mediated hESC differentiation (the enhanced expression of
several lineage markers confirmed differentiation;
Supplementary Figures S1a and b), downregulation of
pluripotency factors NANOG, OCT4, and SOX2 was accom-
panied by a decrease of CDK1 at both the mRNA and protein
levels (Figures 1a–d and Supplementary Figure S1c). The
expression of other cell cycle regulators such as CDK2
remained unchanged (Figure 1b). A correlation between the
downregulation of pluripotency markers and CDK1 was also
observed in human NCCIT during EB- and retinoic
acid-mediated differentiation (Supplementary Figure S1d).
In differentiated EBs, CDK1 was decreased to a level that
was associated with differentiation but retained the ability to
maintain proliferation (Supplementary Figure S1b). Thus,
CDK1 is not only essential for early embryonic development
as a cell cycle driver, but is also associated with the
undifferentiated state of hESCs.
The decreased expression of CDK1 was detected after
lentiviral shRNA-mediated suppression of pluripotency factors
NANOG and OCT4 (Figure 1e). Thus, when hESCs lost their
pluripotency, the corresponding downregulation of CDK1
suggests a true association between CDK1 and the pluripo-
tency state. During hESC differentiation, the expression level
of CDK1 was coupled with NANOG and OCT4, with a higher
level of CDK1 found only in NANOG+high and OCT4+high
populations (Figure 1f). Conversely, CDK1 expression also
associated with NANOG and OCT4 expression, as lower
expression of NANOG and OCT4 was found in cells with
downregulated CDK1 (Figure 1g). Taken together, we
Figure 1 High CDK1 expression is correlated with hESC pluripotent state. (a and b) During EB-mediated differentiation of hESCs, CDK1 expression decreases in parallel
with pluripotency genes NANOG,OCT4, and SOX2 as measured by qRT-PCR (a) and immunoblot (b). (c) qRT-PCR and immunoblot. (d) Measurement of NANOG, OCT4, SOX2,
and CDK1 expression in FBS or retinoic acid-mediated hESC differentiation. qRT-PCR data are represented as the mean±S.D.; n= 2, each in duplicate. (e) Transient
knockdown of NANOG or OCT4 by lentiviral shRNA in hESCs followed by immunoblotting for NANOG, OCT4, and CDK1. (f) Downregulation of CDK1 is associated with a
decrease in NANOG and OCT4 during retinoic acid-mediated differentiation. The CDK1 level presented by the histogram was gated from NANOG+high and NANOG− population
and OCT4+high and OCT4− population, respectively. (g) Decreased NANOG and OCT4 levels might also be associated with the downregulation of CDK1 in retinoic acid-mediated
differentiation. Histogram levels of NANOG and OCT4 were gated from CDK1+high and CDK1+low populations
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demonstrated that the expression level of CDK1 is associated
with pluripotency states.
Downregulation of CDK1 impairs pluripotency and
promotes differentiation. Further to understand CDK1’s
role in hESCs, we decreased the activity of CDK1 either by
lentiviral shCDK1 transduction for 4 days or by treatment
with the CDK1 inhibitor, RO3306 (8 μM) for 2 days. The
mesoendoderm marker transcripts BRACHYURY (BRA),
EOMES, GOOSECOID (GSC), and MIXL1 significantly
increased (Figure 2a, left panel). In contrast, the pluripotency
gene transcripts NANOG, OCT4, and SOX2 (Figure 2a, right
panel), as well as the protein levels of NANOG, OCT4, SOX2,
and SSEA4 (Figure 2b) significantly decreased. Analysis of
hESC colonies with positive alkaline phosphatase activity
demonstrated that self-renewal capacity was impaired after
shCDK1 or RO3306 treatment (Figure 2c and Supplementary
Figure S2a). To further test the effects of CDK1 inhibition on
teratocarcinoma formation in vivo in NCCIT cells, we found
that JNJ-770621 (a CDK1 inhibitor, 0.5 μM) reduced terato-
carcinoma formation from 86 to 31% in SCID mice
(Supplementary Figure S2b). These results suggest that
downregulation of CDK1 impaired self-renewal and triggered
differentiation in hESCs and NCCIT.
Downregulation of CDK1 impairing pluripotency is not
cell cycle and apoptosis regulated. We next investigated
whether the impaired self-renewal of hESCs caused by
CDK1 inactivation was through the traditional role of CDK1 in
regulating the cell cycle and apoptosis. Transient knockdown
of CDK1 by shRNA for 3–4 days did not result in changes in
cell cycle distribution compared with shControl-tranducted
hESCs (Figure 2d and Supplementary Figure S3a).
A different sequence design was also applied to shCDK1 to
exclude off-target effects, which also did not cause cell cycle
arrest (Supplementary Figures S3b and c). Similarly, there
Figure 2 Downregulation of CDK1 promotes differentiation. (a) Transient knockdown of CDK1 by lentiviral shRNA or inactivation of CDK1 by RO3306 (8 μM) resulted in
enhanced mesoendoderm markers (left panel) and decreased pluripotency transcripts (right panel). qRT-PCR data are represented as the mean± S.D., n= 3, each in duplicate.
A statistical comparison was made between shCtrl and shCDK1 or Ctrl and RO3306 by paired Student’s t-test (*Po0.05; **Po0.01; ***Po0.0001). (b) Flow cytometry data
show a reduced expression of the pluripotency proteins NANOG, OCT4, SOX2, and SSEA4 at 2 days after RO3306 (8 μM) treatment. (c) Statistical comparison of alkaline
phosphatase(+) colonies in shCDK1 knockdown or RO3306-treated hESCs. The data are represented as the mean±S.D. from three independent experiments. (d) BrdU-labeled
cell cycle analysis of hESCs that were transiently transduced with lentiviral shCtrl or shCDK1 for 3 days. (e) Flow cytometry analysis of the pluripotency marker TRA-1-60 in
hESCs that were treated with or without 8 μM of RO3306. (f) TRA-1-60 level gating from the live and early apoptotic populations in the RO3306-treated group from (e). (g) Flow
cytometry analysis of NANOG expression in G1, S, and G2/M phases in hESCs that were treated with or without RO3306
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was no significant cell cycle arrest in hESCs after incubation
with RO3306 (8 μM) for 16–28 h, except with a minor
reduction of S phase populations (8%) (Supplementary
Figures S3a, d and e). Thus, the reduction of CDK1 to a
level that does not cause a cell cycle arrest was able to
promote differentiation of hESCs. However, the current study
cannot exclude the possibility that the long-term down-
regulation of CDK1 might affect differentiation and prolifera-
tion via cell arrest.
Interrelation of differentiation, proliferation, and apopto-
sis in CDK1-inactivated hESCs. We investigated the
correlation between differentiation and apoptosis by measur-
ing a pluripotency cellular surface marker (TRA-1-60) in live,
early apoptotic, and dead populations. The overall survival
was comparable between lentiviral shControl- and shCDK1-
transfected hESCs; with or without treatment with RO3306
(2 μM) (Supplementary Figure S4a). Similar results were
obtained using NCCIT cells (Supplementary Figure S4b).
RO3306 (8 μM) treatment for 26 h, the time course with no
significant cell cycle arrests, and a reduced expression of
TRA-1-60 was observed (Figure 2e). By monitoring the
TRA-1-60 expression in different cell populations, we found
that the ratio of hESCs with negative or low TRA-1-60 was
significantly higher in the early apoptotic population than in
the live population (Figure 2f and Supplementary Figure S4c);
although it was concurrent with the slightly enhanced
apoptotic population (compare Supplementary Figure S4a
with d). We postulated that inactivation of CDK1 resulted in
the loss of pluripotency markers at early time points when
cell cycle perturbation was not a major factor. Inactivation of
CDK1-related differentiation exerted further impact on
proliferation and apoptosis of hESCs at later time points.
However, cell cycle interruption, particularly the reduction of
S and induction of G2 arrest, might occur under longer CDK1
perturbation. To monitor cell cycle phase-dependent differ-
entiation, NANOG expression in G1, S, and G2/M phases was
determined. The inactivation of CDK1 led to a shift of NANOG
expression (Supplementary Figure S4e). NANOG expression
was repressed in the G1 phase in comparison with that in the
S and G2 phases. This was not because inactivation of CDK1
resulted in G1 arrest. Moreover, there was no significant
difference in NANOG reduction between the S and G2
phases (Figure 2g). Together, cell cycle perturbation was not
necessary grounds for ESC differentiation; but differentiation
would further affect cellular proliferation and apoptosis.
Impact of CDK1 downregulation on PDK1 phosphoryla-
tion. As CDK1 was associated with the pluripotency state in
an induced differentiation background, this led us to
hypothesize a direct role of CDK1 in monitoring self-
renewal. Predicted kinase cascades in early hESCs differ-
entiation have linked CDK1/CDK2 to the regulation of protein
kinase N,10 which is a substrate of CDK1 in vitro (www.
phosphosite.org). Protein kinase N belongs to the AGC
kinase family and is phosphorylated by 3′-phosphoinositide-
dependent kinase-1 (PDK1), a master kinase for the
activation of other AGC kinases, including Akt.18 To explore
the potential link between CDK1 and PDK1, we found that in
CDK1 knockdown hESCs, phosphorylation of PDK1
(Ser241), which is autophosphorylated and necessary for
PDK1 activity,19 was notably reduced or diminished com-
pared with that in shRNA control-transfected cells
(Figure 3a). Upon the inactivation of CDK1 with RO3306
and JNJ-7706621 (1 μM), which are specific for CDK1 and
had no direct effect on PDK1,20,21 the phosphorylation of
PDK1 was also significantly reduced (Figure 3b). These
results suggest that the suppression of PDK1 phosphoryla-
tion could be the primary effect of CDK1 downregulation. In a
bioinformatic analysis of human PDK1, a putative CDK1
phosphorylation site was identified at Thr354 (TPPK), which
matches the CDK consensus phosphorylation motif (S/T-P-X-
K/R, where X is any amino acid) and is evolutionarily
conserved among human, mouse, and Xenopus PDK1
(Figure 3c). To determine the association between CDK1
and PDK1, co-immunoprecipitation analyses revealed that
CDK1 interacted with PDK1 in vitro (Figure 3d). To further
understand whether Thr354 could be phosphorylated by
CDK1, a CDK1 kinase assay was performed using PDK1
Thr354 wild-type peptide and Thr354A mutant peptide as
substrates. Fluorescence signals indicating ADP generated
by CDK1 kinase activity was significantly higher when using
Thr354 as a substrate than using Thr354A (P=0.03 in H7
and P=0.004 in NCCIT cells) (Figure 3e). Together, these
results suggest that PDK1 is a potential novel functional
substrate of CDK1 and CDK1 inactivation results in the
suppression of PDK1 activity.
Downregulation of CDK1 suppresses the PDK1-PI3K/Akt
pathway. Phosphorylation of Akt at two critical phosphoryla-
tion sites (Thr308 and Ser473) is required for Akt activation.
While Thr308 is phosphorylated by PDK1, Ser473 is
activated directly by mTORC218 and indirectly by
PDK1.22,23 We observed that knockdown of CDK1 in three
lines of hESCs was accompanied by a decrease of
phosphorylation of Akt at Thr308 and Ser473 (Figure 3f),
presumably due to the CDK1 inactivation-mediated suppres-
sion of PDK1 (Figure 3a). We noticed a limited reduction of
Akt phosphorylation in CDK1-inactivated hESCs, probably
because hESC culture medium contains high levels of Akt
activators.13
Although the CDK1 consensus phosphorylation site on
PDK1 (Thr354) is a phosphorylated site, it might not be related
to the inhibition of PDK1 Ser214 phosphorylation after CDK1
inactivation. Thus, we performed co-immunoprecipitation
using an antibody against the phospho-Ser/Thr docking motif
of the PDK1, which covers all serine or threonine phosphor-
ylating motifs, including Thr354, to co-precipitate the active
form of Akt. Considering in addition to Ser214, other
phosphorylated serine or threonine of PDK1 may contribute
to endogenous levels of phospho-Akt. In CDK1 knockdown
hESCs (Figure 3g) and CDK1-inactivated (by RO3306)
NCCIT cells (Figure 3h), the phospho-Ser/Thr docking motif
of PDK1 was inhibited and consequently precipitated less
active form of Akt including pAkt on Ser473 than control cells.
These data demonstrate not only a critical link between CDK1
and PDK1 but also a potential kinase cascade mode of action
of the CDK1-PDK1-Akt signaling pathway. The fact that the
CDK1-PDK1 pathway was able to regulate Akt signaling in
hESCs suggests that in addition to growth factors,13 kinase
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signaling is also important and required for controlling PI3K/
Akt signaling pathways for pluripotency.
Functional CDK1-PDK1-Akt kinase pathway is required
for pluripotency. Following CDK1 knockdown, the
suppressed PDK1-mediated decrease of Akt phosphorylation
was observed even in the mTeSR1 medium, which contains
growth factors for Akt activation. Furthermore, a low dose
of CDK1 inhibitor (RO3306) did not directly inhibit Akt
phosphorylation (Supplementary Figure S5a). Therefore, it
would be critical to understand if CDK1 inactivation affected
the effectors of the PI3K/Akt signaling pathway. We investi-
gated the phosphorylation status of ERK1/2, GSK3β, and
SMAD2/3. In response to reduced Akt phosphorylation
after inactivation of CDK1, the phosphorylation of ERK1/2
(T202, Y204) and GSK3β (Ser9) was enhanced (Figures 4a
and b), indicating an activation of the ERK pathway and
inactivation of GSK3β. These data were also confirmed in
NCCIT cells (Figure 4c). Interestingly, unlike the finding that
SMAD2/3 activity was elevated when Akt activity was lost,13
we did not observe a significant increase in phosphorylation
of SMAD2/3 in shCDK1- or RO3306-treated cells
(Figures 4a–c). As a consequence of the CDK1-PDK1-
PI3K/Akt-mediated alteration of ERK and GSK3β activities,
the addition of a MEK/ERK inhibitor (UO126) blocked the
upregulation of differentiation markers BRA, EOMES, and
GSC and the downregulation of pluripotency markers
NANOG, OCT4, and SOX2 (Figures 4d and e). The CDK1
inhibition-mediated upregulation of differentiation markers
was also reversed with a SMAD2/3 inhibitor (SB431542)
Figure 3 Inactivation of CDK1 specifically modifies the phosphorylation of PDK1 and Akt. (a) The phosphorylation of PDK1 (Ser241) after shCDK1 transduction in hESCs H1
and H7 was analyzed by immunoblotting. (b) Inactivating CDK1 by RO3306 and JNJ-7706621 results in decreased PDK1 phosphorylation in hESCs and NCCIT cells. (c) A CDK1
consensus phosphorylation site S/T-P-X-K/R in PDK1 at Thr354 (TPPK) is evolutionarily conserved among human, mouse, and Xenopus. S/T, serine/threonine; P, proline; X, any
amino acid; K/R, lysine/arginine. (d) NCCIT cell lysates were immunoprecipitated with CDK1 antibody; the bound proteins were analyzed using PDK1 antibody. The loading was
tested by immunoblotting on total PDK1 and CDK1 from equal amount lysates used for IP. (e) CDK1 antibody-immunoprecipitates were subjected to kinase assay using
ADPsensor universal kinase activity assay kit. PDK1 T354 or T354A peptides were used as substrates. Incubating the peptide alone without CDK1 immunoprecipitates was
used as background controls. Relative fluorescence unit (RFU) signals (after subtracting background) were calculated as ΔRFU (RFU2-RFU1) from different reaction time.
*Po0.05, **Po0.01. (f) Transient knockdown of CDK1 in three lines of hESCs suppresses the phosphorylation of Akt at Thr308 and Ser473. (g) The phospho-(Ser/Thr) PDK1
docking motif was immunoprecipitated in shCDK1- or shControl-transduced hESCs. The immunoprecipitates were then analyzed using the antibody to phospho-Akt (Ser473). (h)
The same analysis as in (f) using NCCIT cells that were treated with RO3306 (5 μM) for 24 h
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(Figure 4e). Convincingly, the blockage of differentiation by
UO126 occurred by suppressing ERK activity, thereby
releasing its inhibition of GSK3β (Figure 4f). Furthermore,
the application of the PDK1 activator PS4824 partially
reversed the CDK1 inhibition-mediated differentiation of
hESCs (Figure 4g) through regulating ERK and GSK3β, the
effectors of the PI3K/Akt signal pathway (Figure 4h).
Collectively, these results demonstrate that CDK1-PDK1-Akt
Figure 4 Functional CDK1-PDK1-Akt pathway. (a) Immunoblot analysis of phosphorylated ERK, GSK3β, SMAD2/3, and their total proteins of the effectors of PI3K/Akt
signaling in shControl- and shCDK1-transduced hESCs. (b) Immunoblot analysis of the activity of ERK, GSK3β, and SMAD2/3 in RO3306-treated hESCs. (c) Same analysis as
(b) in NCCIT cells. (d) MEK/ERK inhibitor blocks CDK1 inactivation-mediated differentiation. hESCs were transduced with shControl and shCDK1±UO126 (5 μM), and the
mRNA of mesoendoderm markers (left panel) and pluripotency marker (right panel) were analyzed by qRT-PCR. Paired Student’s t-test was used to compare between shCtrl and
shCDK1; shCDK1 and shCDK1+UO126. *Po0.05, **Po0.01, ***Po0.0001. (e) hESCs were treated with DMSO (Ctrl), RO3306, RO3306+UO126, or RO3306+SB431542.
The mRNA of mesoendoderm markers were analyzed by qRT-PCR. A statistical comparison was made between Ctrl and RO3306; RO3306 and RO3306+UO126; RO3306 and
RO3306+SB431542. (f) Immunoblot analysis of pERK, pGSK3β, pSMAD2/3, and their total proteins in hESCs that were treated with RO3306 or RO3306+UO126. (g) hESCs
were treated with RO3306 or RO3306+PS48 (3 μM), and the mRNA levels of OCT4 (left panel) and the mesoendoderm markers EOMES and GSC (right panel) were analyzed by
qRT-PCR. (h) Immunoblot analysis of pERK, pGSK3β, pSMAD2/3, and their total proteins in hESCs that were treated with RO3306 or RO3306+PS48
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is a functional signaling pathway in controlling the pluripo-
tency of hESCs via the suppression of ERK and maintenance
of GSK3β activity.
Downregulation of CDK1 reduced metabolic glycolysis.
High glycolytic rates have been characterized as metabolic
requirements for the maintenance of pluripotency in many
types of stem cells.25,26 To explore whether CDK1-PDK1-Akt
kinase pathway could modulate metabolic glycolysis in
hESCs, which might further support the hypothesis of CDK1’s
direct role in monitoring pluripotency, other than by regulating
the cell cycle and proliferation. In this connection, it is known
that inhibition of glycolysis does not affect cell proliferation.24
In CDK1-inactivated hESCs, expression of key glycolytic
genes (GLUT1, PFK1, HK2, and LDHA) decreased
significantly, as did lactate production in the culture medium
(Supplementary Figures S6a and b). The decrease in
expression of glycolysis genes was blocked after ERK
suppression (Supplementary Figure S6c) and PDK1
activation (Supplementary Figure S6d). Thus, CDK1
inactivation-mediated hESC differentiation occurs via the
inhibition of the PDK1/Akt signaling pathway and enhances
the effector ERK activity, all of which are involved with
glycolysis regulation.
Cyclin B1-CDK1 complex promotes somatic reprogram-
ming. Given the role of CDK1 in maintaining hESC identity,
we investigated whether CDK1 and its activator cyclin B1
have a role during somatic reprogramming. We observed a
significant increase in the reprogramming efficiency of human
fibroblasts after expressing cyclin B1 or co-expressing cyclin
B1 with CDK1. The expression of CDK1 alone did not
facilitate reprogramming. Furthermore, knocking down CDK1
in the background of cyclin B1 overexpression resulted in no
induced pluripotent stem cells (iPSC) formation (Figure 5a
and Supplementary Figure S7a). These results suggest that
the improvement of iPSC efficiency by cyclin B1 depends on
cyclin B1-CDK1 complexes. Similarly, expression of cyclin B1
promoted reprogramming efficiency in liver cancer epithelial
cells (Figure 5b). The proportion of alkaline phosphatase(+)
iPS colonies was significantly higher after ectopic expression
of cyclin B1 (Figures 5c and d).
Cyclin B1 upregulated LIN28A for iPSC maturation. To
explore the mechanism, pluripotency gene expression
between nascent and replating reprogrammed cells were
compared, as the pluripotency of iPSCs could be lost after
replating.27 OCT4 and SSEA4 were expressed to similar
levels in both vector- and cyclin B1-expressing iPSCs from
the states of nascent to replating. Interestingly, the expres-
sion of NANOG and TRA-1-60, one of the best human
pluripotency markers,27,28 was higher in cyclin B1-expressing
replating iPSCs than in the control cells (Figure 5e and
Supplementary Figure S7b). The western blot of replating
iPSCs displayed a similar result (Figure 5f). Cyclin B1
expression seems to have no notable effect on the cell cycle
or proliferation in nascent or replating iPSCs (Supplementary
Figure S7c). Only a small portion of initially formed iPSCs
completed the reprogramming process and became iPSCs,
whereas most of the iPSCs transitioned from TRA-1-60(+)
into TRA-1-60(− ) cells.27 Thus, in addition to enhancing
reprogramming efficiency, cyclin B1 expression may also
have a role in maintaining pluripotency after replating. We
further found that after reprogramming with OCT4, SOX2,
KLF4, L-MYC (OSKM), LIN28, and p53 shRNA,29 the
expression of NANOG and endogenous OCT4 and SOX2
was comparable, whereas endogenous LIN28A level was
significantly increased in cyclin B1-expressing iPSCs
(Figure 5g), which might contribute to the maintenance of
pluripotency after replating.
We then tried to generate iPSCs in the presence of cyclin B1
expression but without LIN28 (as well as without L-MYC).29
Indeed, iPSC colonies could be produced by the factors
OCT4, SOX2, KLF4, and p53 shRNAwithout L-MYC or LIN28
(Figure 5h and Supplementary Figure S7d). Using this
alternative iPSC system, the levels of NANOG, endogenous
OCT4, and SOX2 were similar in iPSCs derived with iPSC
factors with and without LIN28 (Figure 5i). iPSC colonies
without LIN28 remained in undifferentiated states (Figure 5h)
as well as with NANOG, and endogenous OCT4 and SOX2
expression remained high after replating (Figure 5j).
Importantly, LIN28A and endogenous LIN28A expression
was significantly increased after replating in these iPSCs
(Figure 5k), indicating that cyclin B1-CDK1 complexes can
upregulate and maintain cellular LIN28 expression, which is
critical for iPSC maturation.27
Discussion
We demonstrated that CDK1 was enriched in pluripotent
hESCs and was downregulated during differentiation; and
there was an integrated correlation between the expression of
pluripotency genes and CDK1. Downregulation of CDK1
activity could be manipulated at a level that did not disturb the
cell cycle but still induced differentiation. Together, with the fact
that NANOG levels were similar in different cell cycle phases
during CDK1 inactivation-mediated differentiation, we
propose that the link between ESC cell cycle and cell fate is
not necessarily a consequence of cell cycle alteration, but
rather occurs via a direct role of a cell cycle regulator in
controlling pluripotency. Previous studies have focused on
how cell cycle re-distribution leads to differentiation,30–34
although accumulating evidence suggests the direct control of
pluripotency by cell cycle regulators.35,36 Here, our study adds
specific role of CDK1 in self-renewal and differentiation of
hESCs beyond cell cycle regulation.
We demonstrate that (1) PDK1 is a putative downstream
kinase of CDK1 as PDK1 contains an evolutionarily conserved
CDK1 consensus phosphorylation site at Thr354; (2) CDK1
interacts with PDK1 and CDK1 kinase catalyzes phosphate
transfer on PDK1 Thr354 peptide in vitro. Although we were
not able to demonstrate specific phosphorylation on Thr354
in vivo, the fact that specific suppression of PDK1 phosphor-
ylation and, accordingly, inhibited Akt phosphorylation by
PDK1 when CDK1 was inactivated, indicates that PDK1
contains the specific activating site(s) for CDK1. Note that
instead of PDK1, CDK1 knockdown may also have an impact
on other kinases in affecting Akt activity, as PDK1 is not a
direct kinase of Akt (Ser473). Thus, the inhibition of PDK1-Akt
signaling pathway is responsible for the differentiation
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triggered by the inactivation of CDK1. The evidence that
inhibition of Akt effectors blocked differentiation further
indicates that the CDK1-PDK1-Akt signaling pathway is a
functional pathway for pluripotency of hESCs via suppression
of ERK and maintenance of GSK3β activity. Importantly, in
addition to growth factors, which consistently stimulate and
maintain high Akt signaling for self-renewal,13 CDK1 can
regulate the essential PDK1-Akt signaling pathway for self-
renewal, implicating a new kinase pathway in stem cell biology
and the potential of chemical compounds that selectively
decrease the level of CDK1 activity without perturbing cell
cycle and proliferation for directing differentiation.
Interphase cyclin/CDKs are known to promote somatic
reprogramming via increasing the rate of S phase cells.33,34
We are the first to identify that mitotic driver cyclin B1-CDK1
complexes can increase efficiency of somatic reprogramming,
which is unlikely through promoting cellular proliferation
because co-expression of cyclin B1 with higher level of
CDK1 inhibited iPSC formation (data not shown). Among the
three known factors, LIN28, cyclin D1, and p53 shRNA that
promote reprogramming activities, only LIN28 is considered a
key regulator for iPSC maturation through inhibition of
reprogramming reversion by enhancing TRA-1-60(+)
proliferation and suppressing the conversion of TRA-1-60(+)
Figure 5 Cyclin B1-CDK1 complex promote somatic reprogramming and regulates LIN28A for iPSC maturation. (a) Human fibroblast cells were pre-infected with lentiviral
empty vector, cyclin B1, CDK1, cyclin B1+CDK1, or cyclin B1+shCDK1, followed by iPS episomal transfection and reprogramming induction. The generating efficiency of iPSCs
(%) was calculated by iPSC colonies produced versus cells seeded. (b) The iPSC generation efficiency in liver cancer cells 97 l that were transfected with lentiviral empty vector
or cyclin B1. (c) Alkaline phosphatase(+) iPSC colonies versus total colonies after iPSC replating. *Po0.05. (d) Morphology of AP(+) colony comparison between vector-(upper
panel) and cyclin B1-derived (lower panel) iPSC colonies. (e) Flow cytometry quantification of OCT4 and SSEA4 (left panel) and NANOG and TRA-1-60 (right panel) in nascent
and replating iPS colonies. (f) Immunoblotting comparison of pluripotency proteins between vector- and cyclin B1-derived iPSCs nascent (left panel) and after replating
(right panel). (g) mRNA comparison of NANOG, endogenous (Endo)-OCT4, -SOX2, and -LIN28A between vector- and cyclin B1-expressing iPSCs after replating; n= 2 sets of
iPSCs. (h) Morphology of cyclin B1-expressing iPSCs generated by iPS factors with and without LIN28. (i) mRNA comparison of NANOG, endo-OCT4, and -SOX2 in cyclin
B1-expressing iPSC by iPS factors with and without LIN28. (j) mRNA comparison of NANOG, endo-OCT4, and -SOX2 in nascent and replating cyclin B1-expressing iPSCs by
iPS factors without LIN28. (k) mRNA comparison of LIN28A and endo-LIN28A in nascent- and replating cyclin B1-expressing iPSCs by iPS factors without LIN28. AP, alkaline
phosphatase
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to TRA-1-60(− ) iPSCs, whereas cyclin D1 and p53 shRNA
mainly promote cellular proliferation and suppress cell
death.27 Here we found that cyclin B1-expressing iPSCs
displayed a significantly high level of endogenous LIN28A
exposed to iPS factors with or without exogenously
added LIN28A. Apparently, cyclin B1 is able to upregulate
and maintain cellular levels of LIN28A during reprogramming.
Thus, we raise the possibility that monitoring iPSC factors
could be a new path for improving reprogramming efficiency.
In addition, p53 expression represses transcription of
cyclin B1 and other mitotic regulators.37,38 Application of p53
shRNA for reprogramming releases the repression
and may further benefit reprogramming by cyclin B1
and CDK1.
Cancer cells are known to be refractory to reprogramming.39
Liver cancer cells contain a relatively higher level of
LIN28.40–42 Under cyclin B1 expression, iPSC colonies can
be successfully generated from liver cancer cells by iPS
factors without LIN28A and L-MYC, suggesting that LIN28A
is not a critical refractory factor to reprogramming.
But enhancement of cellular LIN28A by cyclin B1 can
overcome the resistance. Further study is needed to under-
stand the mechanism how cyclin B1-CDK1 regulates LIN28A
or other components for reprogramming. Recently, G2/M cell
cycle regulators have been implicated in maintenance of
pluripotency,43 where cyclin B1-CDK1 promotes iPSCmatura-
tion and provides new evidence from the point of view of
somatic reprogramming.
Together, CDK1 is required for self-renewal of hESCs.
The reduction of CDK1 activity to a level that does not
disturb ESC cell cycling is able to suppress essential PDK1-
PI3K/Akt signaling pathway and promote differentiation
(Figure 6a and b). The sensitivity of hESCs to PI3K/Akt
signaling can be further regulated by the CDK1-PDK1-PI3K/
Akt kinase cascade (Figure 6b). Cyclin B1-CDK1 complexes
are important during reprogramming, probably via regulating
cellular LIN28A for iPSC maturation. This study provides a
novel kinase cascade mechanism for pluripotency control and
acquisition.
Materials and Methods
Cell culture. The hESC lines H1, H7, and H9 were maintained in a feeder-free
mTeSR1 medium (Stemcell Technologies, Vancouver, Canada) on Matrigel (BD
Biosciences, San Jose, CA, USA) or Geltrex (Life Technologies, Grand Island, NY,
USA). NCCIT cells (human pluripotent embryonal carcinoma line) were cultured
according to ATCC’s instructions. Lentivirus particles were produced in 293 T cells
using ViraPower Lentiviral Packaging Mix (Life Technologies) and concentrated by
ultracentrifugation (20 000 × g). hESCs were infected with 1 ml of shRNA lentivirus
for 1 h and then cultured in 50% lentiviral and 50% mTeSR1 medium for 18 h
followed by changing into full mTeSR1 medium to recover.34 hESCs were treated
with CDK1 inhibitor RO3306 (Merck, Kenilworth, NJ, USA) at a dose of 5–8 μM for
2–3 days before further experiments. Other chemical compounds that were used
include UO126, SB431542 (Merck), PS48 (Stemgent, Cambridge, MA, USA), and
JNJ-7706621 (Selleckchem, Houston, TX, USA). DMSO was applied as a vehicle
control. In vitro differentiation of hESC was induced via (1) EB differentiation: the
formation of EBs followed by differentiation in normal growth medium without
βFGF44 (KSR medium); (2) FBS differentiation: EBs were further cultured in
DMEM+20% FBS; and (3) retinoic acid (Sigma-Aldrich, St. Louis, MI, USA)
differentiation: 2–5 μM of retinoic acid was added to hESC or NCCIT cell culture.
Vectors for knockdown and overexpression. Plasmids expressing
shRNAs against human CDK1, NANOG, and OCT4 were constructed using the
pEco-Lenti-H1-shRNA (GFP) kit (GenTarget Inc., San Diego, CA, USA). The oligos
for shRNAs were designed by Life Technologies RNAi Designer or Gene Link
shRNA design program and are listed in Supplementary Information Supplementary
Table S1. Human cyclin B1 and CDK1 genes from hESCs were cloned into pWPI-
lentiviral vector. Human iPSC constructs, including three episomal plasmid vectors
(pCXLE-hOCT3/4-shp53, pCXLE-hSK, and pCXLE-UL) encoding human OCT4,
SOX2, KLF4, LIN28, L-MYC, and p53 shRNA29 were from Addgene.
qRT-PCR. Total RNA isolation, DNase I treatment, and reverse transcription were
performed as previously described.45 Quantitative PCR was performed using the
SYBR Green master mix (Life Technologies) on 7900HT Detection System with
primers listed in Supplementary Information Supplementary Table S1. All the PCRs
were repeated 2–3 times with each run in duplicate and normalized to 18S rRNA.
Relative quantification was calculated as ΔΔCT, which is relative to cells that were
treated with scramble shRNA or vehicle.
Cell cycle analysis and flow cytometry. Cell cycle analysis was
performed using a BrdU and propidium iodide staining assay after fixation as
previously described.46 Cells were stained with antibodies for pluripotency markers
and analyzed using FACSCalibur (BD Biosciences). The antibodies included
NANOG, OCT4, SOX2 (Cell Signaling Technology, Danvers, MA, USA), SSEA4
(BD Biosciences), and TRA-1-60 (Cell Signaling Technology; Biosource, CA, USA).
The MitoProbeDilC1(5) assay kit (Life Technologies) was used to detect live,
apoptotic, and dead cell populations in one staining reaction.
Immunoblot and co-immunoprecipitation. Cell lysates for the western
blots were prepared as described previously.46 Membranes were probed with the
following antibodies: β-actin (Sigma-Aldrich); CDK1 and OCT4 (Santa Cruz
Biotechnology, Dallas, TX, USA); CDK2 (Abcam, Bristol, UK); and phospho-Akt
(Thr308, Ser473), phosphor-ERK1/2 (Thr202/Tyr204), phospho-SMAD2/3
(pSMAD2-Ser465/467, pSMAD3-Ser423/425), phospho-GSK3β (Ser9), phospho-
PDK1 (Ser241), NANOG, OCT4, and SOX2 (Cell Signaling Technology). Co-
immunoprecipitation was performed using phospho- (Ser/Thr) PDK1 docking motif
antibodies and phospho-Akt antibodies. Total cell lysates (100–200 μg) were pre-
cleaned and incubated with phospho-(Ser/Thr) PDK1 docking motif antibody (Cell
Signaling Technology) overnight, before incubated with 50% bead slurry for 2 h.
After five washes, the immune complexes were analyzed by immunoblotting with
anti-phospho-Akt antibodies. Co-immunoprecipitation for assessing interaction was
carried out using CDK1 antibody for immunoprecipitation; the bound proteins were
analyzed by immunoblotting with PDK1 antibody.
Kinase assay. Total cell lysates (200 μg) were pre-cleaned with blank beads
and incubated with CDK1 antibody overnight followed by incubation with 50%
Figure 6 A proposed function of CDK1 in regulating pluripotency. (a) The
correlation of CDK1 activity with embryonic development, cell cycle, and self-renewal/
differentiation. (b) Model of the CDK1-PDK1-PI3K/Akt kinase pathway for self-
renewal and differentiation. CDK1 maintains phosphorylation of PDK1 and
hyperactive Akt (indicated by +) for self-renewal via inhibiting pERK and maintaining
GSK3β activity. Upon the reduction of CDK1 activity, the phosphorylation of PDK1
and Akt is sequentially suppressed (indicated by − ); ERK inhibition is relieved to
suppress GSK3β kinase, which results in stabilization of β-catenin. Subsequently,
pSMAD2/3 and Wnt effectors cooperate to promote differentiation
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protein G bead slurry for 3 h. After five washes (the last two washes using kinase
buffer), the immune complexes were incubated with peptide substrates PDK1
Thr354-WT (ENLHQQTPPKLTA) or Thr354A mutant (ENLHQQAPPKLTA) along
with kinase reaction mix from ADPsensor universal kinase activity assay kit
(BioVision, Milpitas, CA, USA) following the manufacturer’s instructions. Fluorescent
signal at Ex/Em= 535/587 was read using Microplate Fluorescence Reader FL600
(BIO-TEX Instruments, Winooski, VT, USA).
Colony-forming assays and alkaline phosphatase staining. The
AP staining kit (Millipore, Ontario, Canada; Sigma-Aldrich) was used to differentially
stain pluripotent colonies before the number of colonies was quantified.
Lactate production measurement. Lactate production in the culture
medium of hESCs was measured using the Lactate Assay Kit (BioVision) after
RO3306 and other chemical treatments. The hESC cultures that were treated with
vehicles or various chemicals were maintained without changing the medium for
2 days to accumulate lactate.
Somatic cells reprogramming. Pre-infected lentiviral-cyclin B1, CDK1, or
shCDK1 human diploid fibroblasts or liver cancer cells (97 L) were transfected
with equal amount of iPS episomal vectors using electroporation (Lonza, Basel,
Switzerland) followed by passage onto inactivated MEF and switched to iPSC
medium 5–6 days later.29 iPS colony formation was observed and compared
between 14 days and 20 days. The pluripotency of iPSC colonies were stained
for alkaline phosphatase. The reprogramming frequency was calculated in the
percentage of the number of iPS colonies that were generated versus overall
cells that were seeded on MEF. From the first formed iPSCs, several colonies
were randomly picked and passed on to fresh feeder cells for replating.
After replating on MEF, the iPSC colonies were transferred to Geltrex-coated
dishes. iPSC colonies were also generated under feeder-free conditions using
ReproTeSR medium (Stemcell Technologies) following the manufacturer’s
instruction.
Statistical analysis. All data were represented as the mean± S.D. Student’s
t-test (paired or independent t-test) was performed between the controls and
experimental groups using SPSS 21 (IBM Corp., Armonk, NY, USA). A P-value
o0.05 was considered statistically significant.
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